(Q37875489)

24 August 2017

1 reference

title

Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke (English)

1 reference

24 August 2017

1

Peter M Rothwell

1 reference

24 August 2017

2

Ale Algra

1 reference

24 August 2017

3

Pierre Amarenco

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

377

1 reference

24 August 2017

issue

9778

1 reference

24 August 2017

page(s)

1681-1692

1 reference

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Cost of stroke in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

The high cost of not funding stroke research: a comparison with heart disease and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Timing of TIAs preceding stroke: time window for prevention is very short

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

1 reference

7 January 2021

Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Underestimation of the early risk of recurrent stroke: evidence of the need for a standard definition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Population-based study of risk and predictors of stroke in the first few hours after a TIA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Substantial underestimation of the need for outpatient services for TIA and minor stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Systematic review and pooled analysis of published and unpublished validations of the ABCD and ABCD2 transient ischemic attack risk scores

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

ABCD2 score predicts severity rather than risk of early recurrent events after transient ischemic attack.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Prognosis of vertebrobasilar transient ischaemic attack and minor stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Population-based study of delays in carotid imaging and surgery and the risk of recurrent stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Systematic review of associations between the presence of acute ischemic lesions on diffusion-weighted imaging and clinical predictors of early stroke risk after transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Addition of brain infarction to the ABCD2 Score (ABCD2I): a collaborative analysis of unpublished data on 4574 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Addition of brain and carotid imaging to the ABCD² score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Systematic review of the operative risks of carotid endarterectomy for recently symptomatic stenosis in relation to the timing of surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Blood pressure as a prognostic factor after acute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Antihypertensive treatment after stroke and all-cause mortality--an analysis of the General Practitioner Research Database (GPRD).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

A survey on compliance with secondary stroke prevention guidelines and follow up for the inpatients with atherosclerotic cerebral infarction/transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Anticoagulation for secondary stroke prevention: another nail in the coffin?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Digestion of the antiplatelets comparison of PRoFESS: 18-7=1?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Triflusal for preventing serious vascular events in people at high risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Predisposing factors for cerebral infarction: the Oxfordshire community stroke project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Status of the epidemiology of atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Demography. Broken limits to life expectancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Validation of Clinical Classification Schemes for Predicting Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Apixaban in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Nonfasting triglycerides and risk of ischemic stroke in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Major lipids, apolipoproteins, and risk of vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Telmisartan to prevent recurrent stroke and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Medium-term variability of blood pressure and potential underdiagnosis of hypertension in patients with previous transient ischemic attack or minor stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960516-3

7 January 2021

10.1016/S0140-6736(11)60516-3

Identifiers

DOI

1 reference

24 August 2017

1 reference